Richard Mulligan

October 17, 2026

IFF to Report Q3 2026 Results on November 3. International Flavors & Fragrances is scheduled to release its third-quarter 2026 earnings on November 3, 2026. This upcoming report is the primary driver of recent attention for the stock. The company's shares have been trading near the upper end of their 52-week range, with an RSI of 75.3 suggesting strong recent momentum ahead of the announcement.

October 12, 2026

BHC appoints interim CEO and looks to raise FY26 EBITDA guidance. Bausch Health announced that its chairman, Thomas J. Appio, will serve as interim chief executive effective immediately. The company and its parent also said they expect to raise the adjusted EBITDA guidance for fiscal year 2026, not including the recently acquired IPR&D business. A separate notice confirms that the firm will release its third‑quarter 2026 results on October 28. Analysts at Zacks included Bausch Health in a recent coverage roundup, highlighting the stock among other health‑care names.

October 15, 2026

Sana Biotechnology Featured in Diabetes Treatment Analysis. Sana Biotechnology was the subject of a recent analysis titled 'A Shot At Diabetes,' which likely examines the company's potential in treating the condition. This coverage places the stock in the spotlight for investors watching biotech developments. The stock is currently trading near its support level, with an RSI indicating it may be oversold.

October 17, 2026

Biogen sees kidney therapy progress and rating upgrade. Biogen is receiving attention after a kidney transplant milestone was reported, highlighting its involvement in kidney disease research. The company’s partner Estuary Therapeutics raised $93 million to advance a gene‑therapy for kidney disease, adding to the pipeline focus. Analysts have upgraded Biogen’s outlook, noting growth potential beyond its Alzheimer’s products. An earnings preview also points to upcoming results that could shape market views.